Chugai Pharmaceutical (CHGCF) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for joining Chugai Pharmaceutical's earnings call on the financial results for the fiscal year 2024 third quarter. I am Miata from Corporate Communications Department. I'd like to serve as your moderator today. Today, we have an on-site presentation as well as a Zoom webinar, and today's agenda is in the document distributed. And today's call is going to be held in Japanese, but through the Zoom webinar, you will be able to listen to the simultaneous interpretation in English. Please find the interpretation mark at the bottom of the screen and select the language of your choice. We will take questions after the presentations. We plan to have 30 minutes for the question and answer session following the presentations. During the presentations, please allow us to mute your microphones. We thank you for your cooperation. Now, Dr. Osamu Okuda is going to present the fiscal year 2024 third quarter overview. Okuda, the President. I'd like to give you the third quarter of financial year 2024. Please take a look at page 5. Up to the third quarter, we have achieved increased revenue and profit, and revenue increased by 3.7% year-on-year. This is a turnaround from the slight decrease in the revenue in the second quarter. Operating profit increased by 25.3% year-on-year, so it has continued to increase year-on-year, and both are higher than our original forecast. Domestic sales decreased significantly due to the completion of government supply of loan-approved, which was recorded last year, and NHI drug price revisions, as well as the impact of generics. Overseas sales and other revenue increased significantly, particularly due to exports of Hemlibra, the in-house product, to Roche and Royalty Income. Based on the strong performance, which exceeded original expectation...